Partnering with BI Sincerely, Yours - Boehringer Ingelheim
Partnering with BI Sincerely, Yours - Boehringer Ingelheim
Partnering with BI Sincerely, Yours - Boehringer Ingelheim
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Dr. Claude Gimmi<br />
Global Licensing Oncology<br />
Biberach, Germany<br />
Phone: +49 7351 54 94607<br />
Fax: +49 7351 83 94607<br />
E-mail: claude.gimmi@boehringer-ingelheim.com<br />
Recent advances in tumor biology and genome research have widened the scope of innovative<br />
opportunities for the treatment of cancer. New therapies <strong>with</strong> significantly improved treatment<br />
success rates are on the horizon. Our strong focus on front-line research has allowed us to<br />
rapidly build a strong oncology pipeline <strong>with</strong> several compounds in clinical phases I-III for a<br />
variety of cancer types.<br />
We are looking for partners <strong>with</strong> the same passion to seek new and better treatment options<br />
for cancer patients.<br />
Oncology<br />
Key Areas for <strong>Partnering</strong><br />
• Solid and hematologic cancer indications<br />
• Targeted signal transduction inhibitors<br />
(including compounds targeting mitogenic<br />
pathways, pro-apoptotic pathways,<br />
metabolic pathways), inhibitors of tumor<br />
angiogenesis<br />
• Small molecules as well as monoclonal<br />
antibodies and protein therapeutics<br />
• Mechanisms or approaches <strong>with</strong> the<br />
potential to be clearly differentiated bestin-class<br />
or first-in-class therapies<br />
Excluded Areas<br />
• RNAi and antisense<br />
• Gene therapy<br />
• Radio-immunotherapy<br />
• Cellular vaccines<br />
• Viral-mediated approaches<br />
• Adjunct/supportive therapy<br />
18 Oncology<br />
19
Change language